Thrombosis Digest 2018

Interpreting Safety Results of NOACs Based on Bleeding Risk

2018-12-18

Non-vitamin K antagonist oral anticoagulant (NOAC) treatment can reduce the risk of stroke in patients with atrial fibrillation (AF).

Managing the multi-morbid patient with AF: Focus on patients with renal impairment

2018-12-15

Most patients who suffer from a chronic condition have multiple co-morbidities, making it difficult to manage the benefits and risks of multiple recommended treatments.

Professor Craig I. Coleman about challenges in interpreting real-world studies involving the NOACs

3_16_TA_PE_guidelines_diagrams_thumbnail

2018-10-19

Phase III randomized controlled trials (RCTs) are viewed as the gold standard for comparing the efficacy and safety of a new drug with an existing drug. RCTs assess whether a drug works under strict conditions in a carefully selected patient population and using a set protocol.

Residual MACE in CAD: What Are the Long-Term Adverse Cardiac Events to Worry About?

2018-09-23

Symptomatic coronary artery disease (CAD) affects over 150 million patients worldwide and is caused when atherosclerotic plaques form in the coronary arteries, limiting blood flow to the heart. The rupture of one of these plaques can lead to the formation of a blood clot, which partially or completely blocks blood flow, leading to an acute myocardial infarction (MI).

Join more than 1.500 of your peers to stay up to date with the latest in thrombosis.

See Also

Thrombosis Digest 2018

Interpreting Safety Results of NOACs Based on Bleeding Risk

Interpreting Safety Results of NOACs Based on Bleeding Risk

Managing the multi-morbid patient with AF: Focus on patients with renal impairment

Managing the multi-morbid patient with AF: Focus on patients with renal impairment

Professor Craig I. Coleman about challenges in interpreting real-world studies involving the NOACs

Professor Craig I. Coleman about challenges in interpreting real-world studies involving the NOACs

Residual MACE in CAD: What Are the Long-Term Adverse Cardiac Events to Worry About?

Residual MACE in CAD: What Are the Long-Term Adverse Cardiac Events to Worry About?

Join the conversation!

Thrombosis Adviser

Join more than 1.500 of your peers to stay up to date with the latest in thrombosis.

See Also

Peripheral Artery Disease: causes and consequences

Coronary Artery Disease: causes and consequences

Thrombosis Digest 2018

Interpreting Safety Results of NOACs Based on Bleeding Risk

Interpreting Safety Results of NOACs Based on Bleeding Risk

Interpreting Safety Results of NOACs Based on Bleeding Risk

Managing the multi-morbid patient with AF: Focus on patients with renal impairment

Managing the multi-morbid patient with AF: Focus on patients with renal impairment

Managing the multi-morbid patient with AF: Focus on patients with renal impairment

Professor Craig I. Coleman about challenges in interpreting real-world studies involving the NOACs

Professor Craig I. Coleman about challenges in interpreting real-world studies involving the NOACs

Professor Craig I. Coleman about challenges in interpreting real-world studies involving the NOACs

Residual MACE in CAD: What Are the Long-Term Adverse Cardiac Events to Worry About?

Residual MACE in CAD: What Are the Long-Term Adverse Cardiac Events to Worry About?

Residual MACE in CAD: What Are the Long-Term Adverse Cardiac Events to Worry About?

Join the conversation!